|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Neoptolemos JP, Stocken DD, Friess H,
Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C,
Lacaine F, et al: A randomized trial of chemoradiotherapy and
chemotherapy after resection of pancreatic cancer. N Engl J Med.
350:1200–1210. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oettle H, Neuhaus P, Hochhaus A, Hartmann
JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J,
Arning MB, et al: Adjuvant chemotherapy with gemcitabine and
long-term outcomes among patients with resected pancreatic cancer:
The CONKO-001 randomized trial. JAMA. 310:1473–1481. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eguchi H, Nagano H, Tanemura M, Takeda Y,
Marubashi S, Kobayashi S, Kawamoto K, Wada H, Hama N, Akita H, et
al: Preoperative chemoradiotherapy, surgery and adjuvant therapy
for resectable pancreatic cancer. Hepatogastroenterology.
60:904–911. 2013.PubMed/NCBI
|
|
5
|
Evans DB, Varadhachary GR, Crane CH, Sun
CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA,
et al: Preoperative gemcitabine-based chemoradiation for patients
with resectable adenocarcinoma of the pancreatic head. J Clin
Oncol. 26:3496–3502. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ohigashi H, Ishikawa O, Eguchi H,
Takahashi H, Gotoh K, Yamada T, Yano M, Nakaizumi A, Uehara H,
Tomita Y, et al: Feasibility and efficacy of combination therapy
with preoperative full-dose gemcitabine, concurrent
three-dimensional conformal radiation, surgery, and postoperative
liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg.
250:88–95. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bates S, Rowan S and Vousden KH:
Characterisation of human cyclin G1 and G2: DNA damage inducible
genes. Oncogene. 13:1103–1109. 1996.PubMed/NCBI
|
|
8
|
Kasukabe T, Okabe-Kado J, Honma Y and
Cotylenin A: a new differentiation inducer and rapamycin
cooperatively inhibit growth of cancer cells through induction of
cyclin G2. Cancer Sci. 99:1693–1698. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Padua MB and Hansen PJ: Changes in
expression of cell-cycle-related genes in PC-3 prostate cancer
cells caused by ovine uterine serpin. J Cell Biochem.
107:1182–1188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao Z, Liu Y, He H, Chen X, Chen J and Lu
YC: Candidate genes influencing sensitivity and resistance of human
glioblastoma to Semustine. Brain Res Bull. 86:189–194. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Naito Y, Yabuta N, Sato J, Ohno S, Sakata
M, Kasama T, Ikawa M and Nojima H: Recruitment of cyclin G2 to
promyelocytic leukemia nuclear bodies promotes dephosphorylation of
γH2AX following treatment with ionizing radiation. Cell Cycle.
12:1773–1784. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choi MG, Noh JH, An JY, Hong SK, Park SB,
Baik YH, Kim KM, Sohn TS and Kim S: Expression levels of cyclin G2,
but not cyclin E, correlate with gastric cancer progression. J Surg
Res. 157:168–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hasegawa S, Eguchi H, Nagano H, Konno M,
Tomimaru Y, Wada H, Hama N, Kawamoto K, Kobayashi S, Nishida N, et
al: MicroRNA-1246 expression associated with CCNG2-mediated
chemoresistance and stemness in pancreatic cancer. Br J Cancer.
111:1572–1580. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li WJ, Liu GL, Yu F, Xiang XX, Lu YF, Xiao
HZ and Shi YP: CCNG2 suppressor biological effects on thyroid
cancer cell through promotion of CDK2 degradation. Asian Pac J
Cancer Prev. 14:6165–6171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun GG, Zhang J and Hu WN: CCNG2
expression is downregulated in colorectal carcinoma and its
clinical significance. Tumour Biol. 35:3339–3346. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun GG, Hu WN, Cui DW and Zhang J:
Decreased expression of CCNG2 is significantly linked to the
malignant transformation of gastric carcinoma. Tumour Biol.
35:2631–2639. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen JQ, Liu CJ, Wen HX, Shi CL, Zhang HS,
Li M and Sun GG: Changes in the expression of cyclin G2 in
esophageal cancer cell and its significance. Tumour Biol. 2014.
|
|
18
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumors (7th). Wiley-Blackwell.
Oxford: 2009.
|
|
19
|
Kondo M, Yamamoto H, Nagano H, Okami J,
Ito Y, Shimizu J, Eguchi H, Miyamoto A, Dono K, Umeshita K, et al:
Increased expression of COX-2 in nontumor liver tissue is
associated with shorter disease-free survival in patients with
hepatocellular carcinoma. Clin Cancer Res. 5:4005–4012.
1999.PubMed/NCBI
|
|
20
|
Ito Y, Yoshida H, Uruno T, Nakano K,
Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma K,
et al: Decreased expression of cyclin G2 is significantly linked to
the malignant transformation of papillary carcinoma of the thyroid.
Anticancer Res. 23:2335–2338. 2003.PubMed/NCBI
|
|
21
|
Kim Y, Shintani S, Kohno Y, Zhang R and
Wong DT: Cyclin G2 dysregulation in human oral cancer. Cancer Res.
64:8980–8986. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fu G and Peng C: Nodal enhances the
activity of FoxO3a and its synergistic interaction with Smads to
regulate cyclin G2 transcription in ovarian cancer cells. Oncogene.
30:3953–3966. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Montagner M, Enzo E, Forcato M, Zanconato
F, Parenti A, Rampazzo E, Basso G, Leo G, Rosato A, Bicciato S, et
al: SHARP1 suppresses breast cancer metastasis by promoting
degradation of hypoxia-inducible factors. Nature. 487:380–384.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ahmed S, Al-Saigh S and Matthews J: FOXA1
is essential for aryl hydrocarbon receptor-dependent regulation of
cyclin G2. Mol Cancer Res. 10:636–648. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cui DW, Cheng YJ, Jing SW and Sun GG:
Effect of cyclin G2 on proliferative ability of prostate cancer
PC-3 cell. Tumour Biol. 35:3017–3024. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cui DW, Sun GG and Cheng YJ: Change in
expression of cyclin G2 in kidney cancer cell and its significance.
Tumour Biol. 35:3177–3183. 2014. View Article : Google Scholar : PubMed/NCBI
|
